CME Group Inc. (CME)

FairStock Score: 53/100 — MIXED

Key Financials

Strengths

• Exceptional 71.75% net margin and recurring revenue model demonstrate pricing power and operational excellence
• Strong Piotroski F-Score of 8/9 indicates high-quality earnings and robust financial fundamentals
• Dominant market position in global futures and derivatives clearing creates durable competitive moats
• Conservative balance sheet with 0.13 D/E ratio and consistent free cash flow generation of $837.3M
• Low beta of 0.26 provides portfolio stability and defensive characteristics in market volatility

Concerns

• Valuation is deeply unjustifiable—trading at $317 versus Graham Number of $76.50 reflects 314% negative margin of safety
• Astronomical EV/EBITDA multiple of 66.3x leaves no room for disappointment or market normalization
• Anemic FCF yield of 1.0% and low ROCE of 1.58% raise questions about return on invested capital
• Concerning Altman Z-Score of 0.50 and lack of visible revenue growth create uncertainty about sustainability

AI Analysis

CME Group presents a fascinating paradox—a genuinely excellent business trading at an alarmingly expensive price. Let me be direct: this is not a bargain. The company operates a durable monopoly-like franchise in global futures and derivatives clearing, with 71.75% net margins and exceptional free cash flow of $837.3M annually. The business is fundamentally sound—low leverage at 0.13 D/E, a remarkable Piotroski score of 8/9, and dominant market position create genuine competitive moats. However, I cannot ignore the valuation mathematics. At $317.10 with a Graham Number of just $76.50, we're facing a negative margin of safety exceeding 300%. The EV/EBITDA multiple of 66.3x is astronomical, even for quality compounders. CME's ROE of 14.75% is respectable but hardly justifies paying four times book value. The FCF yield of 1.0% is inadequate compensation for equity risk. Yes, the low beta of 0.26 indicates stability, but stability at 4x fair value isn't a bargain—it's a trap for undisciplined capital. Growth appears muted without visible revenue acceleration, and the Altman Z-Score of 0.50 raises concerning questions about financial structure despite strong cash generation. This is a best-in-class operator, but I've learned that even exceptional businesses become poor investments at unreasonable prices.

Bull Case

CME's monopolistic control over global derivatives clearing ensures secular growth as financial markets expand and regulatory requirements for central clearing increase. Rising geopolitical tensions and economic uncertainty typically boost volatility and trading volumes, directly benefiting CME's volume-dependent revenue model.

Bear Case

Market normalization or a prolonged period of reduced volatility could compress CME's premium valuation rapidly. At current valuations, any hint of earnings disappointment or revenue deceleration could trigger significant downside, leaving shareholders with inadequate returns for the risk undertaken.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer